Axogen Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: Axogen Inc is far larger — about 5.2× Ginkgo Bioworks Holdings Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | DNA | |
|---|---|---|
Market Cap | $2.61B | $505.73M |
Sector | Technology | Health |
52-Week High | $48.48 | $16.14 |
52-Week Low | $14.16 | $5.48 |
Enterprise Value | $2.52B | $607.68M |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →